C O M M U N I C A T I O N S
Table 1. Kinetic Study of the Transamination Reaction under Various Conditionsa
entry
pyridoxamine
polymer
ktransamination (min-1
)
krelative
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
A
A
B
C
D
E
E
E
E
E
E
E
E
E
E
no polymer
P4VIm
P4VIm
P4VIm
(1.4 ( 0.3) × 10-6
1.00b
100
500
(1.4 ( 0.2) × 10-4
(7.0 ( 0.2) × 10-4
(1.3 ( 0.1) × 10-2
(3.3 ( 0.2) × 10-2
(1.7 ( 0.1) × 10-1
(31.2 ( 0.1) × 10-3
(1.2 ( 0.1) × 10-2
(1.4 ( 0.1) × 10-1
(1.5 ( 0.1) × 10-1
(1.2 ( 0.1) × 10-1
(1.3( 0.1) × 10-1
(1.1 ( 0.1) × 10-1
(6.9 ( 0.1) × 10-2
-
9300
P4VIm
23600
121400
22300
8600b
100000
107200
85700
92900
78600
49300
-
P4VIm 0% dodecylated
P1VIm 0% dodecylated
PEI 0% dodecylated
P4 VIm 0% dodecylatedc
P4 VIm 0% dodecylatedd
P4VIm 2.3% dodecylated
P4VIm 4.5% dodecylated
P4VIm 10.1% dodecylated
P4VIm 14.8% dodecylated
P4VIm 30% dodecylated
a Reaction conditions: 1.5 × 10-4 mol/L pyridoxamine, 37.5 mg/L polymer, 5.0 × 10-3 mol/L pyruvic acid, 2.0 × 10-3 mol/L EDTA, 20 °C, pH 7.5.
b Data from ref 2. c Polymerization was done with 5 mol % AIBN instead of the normal 1 mol %. d Polymerization was done with 5 mol % AIBN
instead of the normal 1 mol % and 8 mol % chain-transfer agent (CTA) reagent.
(entry 9) had similar rates with cofactor E. We found that simple
P4VIm with cofactor E (entry 6) was 14-fold more effective as a
catalyst than our polyaziridine without dodecyl groups under the
same conditions (entry 8). Poly(1-vinylimidazole) (P1VIm) was also
prepared (see the Supporting Information), and the transamination
rate was determined to be enhanced 22 300-fold (entry 7), meaning
that P1VIm is only 2.6-fold more effective than the polyaziridine
(entry 8).
of oxazoline ionic polymerization, as we employed previously with
phenylalanine derivatives.11 Since those ionic polymers are not only
almost monodisperse but also isotactic, retaining the chirality of
the parent amino acids, analogues derived from histidine could well
be polyimidazoles with useful chiral selectivities for products and
starting materials.
Acknowledgment. We thank the NIH and NSF for financial
support of this work. R.S. has an FQRNT (Fonds Que´be´cois de la
Recherche sur la Nature et les Technologies) postdoctoral fellow-
ship. We thank Dr. Mary Ann Gawinowicz from the Protein Core
Facility at Columbia University College of Physicians & Surgeons
for the MALDI-TOF experiments.
Our copolymers with dodecyl groups are more effective with
phenylpyruvic acid than with simple pyruvic acid. This reflects the
better binding of a hydrophobic substrate into the more hydrophobic
polymer. The reaction of phenylpyruvic acid was too rapid to follow
by the UV method under our conditions, so we determined the
selectivity of a competition reaction using 30:30:1 phenylpyruvic
acid/pyruvic acid/pyridoxamine derivative mixture to form a
phenylalanine/alanine ratio that was determined by HPLC, as
previously.2 We observed a ratio of 3:1 for the reaction using simple
P4VIm and (19 ( 1):1 for the reaction with the copolymer having
4.5% dodecylated monomer. The latter is slightly higher than the
14:1 ratio we had seen previously with the dodecylated polyaziri-
dine.2 Since amination by this imidazole copolymer (entry 12) was
92 900-fold more rapid than the reaction without polymer, and since
we had shown previously that simple pyridoxamines aminate
pyruvic acid and phenylpyruvic acid at the same rate,10 this means
that the acceleration of the amination of phenylpyruvic acid by the
polymer with cofactor E is (1.77 ( 0.1) × 106 (i.e., almost
2-million-fold). The amination of indolepyruvic acid, forming
tryptophan, was accelerated (3.9 ( 0.1) × 106-fold (i.e., 4-million-
fold) under the same conditions.
Supporting Information Available: Synthesis procedures and
pertinent spectra. This material is available free of charge via the
References
(1) Artificial Enzymes; Breslow, R., Ed.; Wiley-VCH: Weinheim, Germany,
2005.
(2) Liu, L.; Zhou, W. J.; Chruma, J.; Breslow, R. J. Am. Chem. Soc. 2004,
126, 8136.
(3) (a) Zhou, W. J.; Liu, L.; Breslow, R. HelV. Chim. Acta 2003, 86, 3560. (b)
Liu, L.; Breslow, R. Bioorg. Med. Chem. 2004, 12, 3277.
(4) Delaney, E. J.; Wood, L. E.; Klotz, I. M. J. Am. Chem. Soc. 1982, 104,
799.
(5) Suh, J. Synlett 2001, 1343, and references therein.
(6) Hollfelder, F.; Kirby, A. J.; Tawfik, D. S. J. Org. Chem. 2001, 66, 5866.
(7) (a) Liu, L.; Breslow, R. J. Am. Chem. Soc. 2002, 124, 4978. (b) Liu, L.;
Rozenman, M.; Breslow, R. J. Am. Chem. Soc. 2002, 124, 12660.
(8) Zhao, H.; Foss, F. W.; Breslow, R. J. Am. Chem. Soc. 2008, 130, 12590.
(9) (a) Overberger, C. G.; Vorcheheimer, N. J. Am. Chem. Soc. 1963, 85, 951.
(b) Overberger, C. G.; Corett, R.; Salamone, J. C.; Yaroslavsky, S.
Macromolecules 1968, 1, 331. (c) Overberger, C. G.; Shen, C.-M. Bioorg.
Chem. 1971, 1, 1. (d) Overberger, C. G.; Glowaky, R. C.; Vandewyer,
P. H. J. Am. Chem. Soc. 1973, 95, 6008.
The use of these polyvinylimidazoles in the benzoin condensation
with thiazolium and imidazolium coenzyme mimics is under
investigation. We are also pressing forward with an attempt to
produce polymers with smaller polydispersity, including the use
(10) Breslow, R.; Hammond, M.; Lauer, M. J. Am. Chem. Soc. 1980, 102, 421.
(11) Bandyopadhyay, S.; Zhou, W. J.; Breslow, R. Org. Lett. 2007, 9, 1009.
JA9072589
9
J. AM. CHEM. SOC. VOL. 131, NO. 43, 2009 15605